Application Testing Sample Clauses

Application Testing. The Sandbox Test Environment (the “Sandbox”) is a test environment for testing Applications to ensure error-free operation prior to release. You may use information made available in the Sandbox only to develop and test your Application, and you must delete your Application from the Sandbox immediately after testing is completed.
Sample 1Sample 2
AutoNDA by SimpleDocs
Application Testing a. IBM will perform the following test services for Applications developed or modified by IBM or for application software developed or modified by Third Party service provider(s) as set forth in Schedule F (Software):
Sample 1
Application Testing. TKJ Inc. has provided control samples for application testing purposes to Cyberlux Corporation. TKJ Inc has also been conducting application testing at our facilities in Northbrook for approximately 12 weeks. Information derived from the combined test results and comments from both Cyberlux and TKJ Inc shall be used to accomplish final design revisions prior to the release of the design for production. Cyberlux Corporation agrees to due diligence in application testing the products for suitability for intended use. This application testing may include use in actual final environment by end users or "field test" participants prior to any high volume production run.
Sample 1
Application Testing a) At Rogers’ request, prior to ramping the production rollout, the Customer shall provide to Rogers, at no cost to Rogers, the then current application software used on the Devices (the “Application”), and associated documentation in order for Rogers to run and test such Application with the Devices to ensure network integrity and that the Application will not adversely affect Rogers Facilities or other Customers of Rogers (the “Rogers Application Testing”).
Sample 1
Application Testing. Developer shall test the Application for use with E*TRADE System. E*TRADE reserves the right to perform, but is not obligated to perform, acceptance testing of the Application, and Developer will provide reasonable cooperation with E*TRADE should it desire to test the functions. Such testing by E*TRADE shall not create any obligations on the part of E*TRADE with respect to the Application, and Developer will not disclose in any manner to any Third-Party that E*TRADE has performed testing of the Application, or the results of any such testing undertaken by E*TRADE. The Developer will not make the functions of the Application available to End Users until the Application performs in accordance with the specifications and documentation for such Application and the functions have been tested and approved by Developer.
Sample 1

Related to Application Testing

  • Testing Landlord shall have the right to conduct annual tests of the Premises to determine whether any contamination of the Premises or the Project has occurred as a result of Tenant’s use. Tenant shall be required to pay the cost of such annual test of the Premises; provided, however, that if Tenant conducts its own tests of the Premises using third party contractors and test procedures acceptable to Landlord which tests are certified to Landlord, Landlord shall accept such tests in lieu of the annual tests to be paid for by Tenant. In addition, at any time, and from time to time, prior to the expiration or earlier termination of the Term, Landlord shall have the right to conduct appropriate tests of the Premises and the Project to determine if contamination has occurred as a result of Tenant’s use of the Premises. In connection with such testing, upon the request of Landlord, Tenant shall deliver to Landlord or its consultant such non-proprietary information concerning the use of Hazardous Materials in or about the Premises by Tenant or any Tenant Party. If contamination has occurred for which Tenant is liable under this Section 30, Tenant shall pay all costs to conduct such tests. If no such contamination is found, Landlord shall pay the costs of such tests (which shall not constitute an Operating Expense). Landlord shall provide Tenant with a copy of all third party, non-confidential reports and tests of the Premises made by or on behalf of Landlord during the Term without representation or warranty and subject to a confidentiality agreement. Tenant shall, at its sole cost and expense, promptly and satisfactorily remediate any environmental conditions identified by such testing in accordance with all Environmental Requirements. Landlord’s receipt of or satisfaction with any environmental assessment in no way waives any rights which Landlord may have against Tenant.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

Time is Money Join Law Insider Premium to draft better contracts faster.